Nayak Sanjay 4

What Happened

• Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix (OCUL), reported a sale of 1,858 shares of common stock on May 26, 2026. The weighted average sale price was $8.20 per share for a total proceeds of approximately $15,236. This was a sale (not a purchase) and appears to be a routine sell-to-cover tax withholding transaction tied to RSU vesting, not a discretionary market trade.

Key Details

• Transaction type: Sale (S) on 2026-05-26; Form 4 filed 2026-05-28 (timely).
• Shares sold: 1,858 at a weighted average price of $8.20; reported price range $8.1440–$8.2512 (multiple executions). Reporting person can provide a per-price breakdown on request (footnote F2).
• Reason/footnote: Sale executed under a durable automatic sale instruction adopted Feb 21, 2024, to effect a sell-to-cover election to satisfy tax withholding for RSUs that vested May 22, 2026 (footnote F1). The filing states the sales were not a discretionary trade by the reporting person.
• Shares owned after transaction: Not specified in the information provided in this summary.

Context

• Sell-to-cover transactions are common when restricted stock units vest and are used to pay taxes; they do not necessarily indicate management sentiment about the company’s outlook. This was not an option exercise or a gift—just a tax-withholding sale tied to RSU vesting.